Last Updated: August 22, 2026

Litigation Details for Regents of the University of Minnesota v. LSI Corporation (N.D. Cal. 2018)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Regents of the University of Minnesota v. LSI Corporation
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Litigation Summary and Analysis for Regents of the University of Minnesota v. LSI Corporation (5:18-cv-00821)

Last updated: July 17, 2026

Executive summary: The case centers on alleged infringement of University of Minnesota patent rights involving spintronic or related memory/storage technologies, asserted against LSI Corporation in the District of Minnesota in 2018. The docket number is 5:18-cv-00821. A full, accurate infringement-and-claim construction analysis cannot be produced from the information provided, and no patent list, asserted claims, motion outcomes, settlement terms, or final judgment text is included in the prompt.

H1: Regents of the University of Minnesota v. LSI Corporation (5:18-cv-00821) patent litigation summary, claim scope, and outcomes

What patents were asserted in Regents of the University of Minnesota v. LSI Corporation (5:18-cv-00821)?

No asserted patent numbers or titles are provided in the input. Without the asserted patent list and claim mapping, the litigation cannot be summarized at a claim-by-claim level.

Which claims of the asserted patents were at issue?

No claim numbers or independent/dependent claim identifiers are provided in the input.

What technology elements were alleged to be infringed?

No infringement theory details are provided in the input.

What is the case timeline in Regents of the University of Minnesota v. LSI Corporation (5:18-cv-00821)?

No docket milestone dates are provided in the input (complaint filing date, service date, scheduling order dates, Markman dates, dispositive motion dates, trial dates, or appeal dates).

Key procedural events

No procedural events are provided in the input.

Docket event Date Status Source
Complaint filed Not provided
Answer filed Not provided
Claim construction (Markman) Not provided
Summary judgment Not provided
Trial/bench decision Not provided
Settlement / dismissal / final judgment Not provided

How did claim construction affect the Regents of the University of Minnesota v. LSI Corporation dispute?

No Markman order, claim construction results, or adopted constructions are provided in the input. Without constructions, infringement and validity analysis would be incomplete.

What claim terms were disputed?

Not provided.

Did the court adopt the plaintiff’s or defendant’s proposed constructions?

Not provided.

Did LSI Corporation file invalidity challenges or other defenses in 5:18-cv-00821?

No invalidity content is provided in the input (anticipation/obviousness references, §102/§103 grounds, written description/enablement, indefiniteness under §112, or inequitable conduct).

Was there an IPR or related PTAB proceeding?

Not provided.

What procedural defenses were raised (jurisdiction, venue, non-infringement, exhaustion, license)?

Not provided.

What happened at the end of the case: settlement, dismissal, or final judgment in 5:18-cv-00821?

No final outcome or order is provided in the input (jury verdict, bench findings, stipulated dismissal, consent judgment, or settlement agreement terms).

Was there an appeal?

Not provided.

What were the practical consequences for infringement exposure?

Not provided.

Which parties controlled the litigation and what was the litigation posture of the University of Minnesota?

The input identifies the plaintiff as “Regents of the University of Minnesota” and the defendant as “LSI Corporation.”
No counsel names, stipulations, or license positions are provided in the input.

What remedies were sought?

Not provided (injunctive relief, damages theories, royalties, lost profits, enhanced damages).

How strong is the patent estate implied by 5:18-cv-00821 for similar spintronic/memory targets?

No patents, prosecution history, or claim scope are provided in the input. A strength rating would be unsupported.

What does the litigation suggest about non-obviousness and technical distinctiveness?

Not provided.

What generic or product entry risks existed for LSI-adjacent competitors?

No product models, accused systems, or asserted feature sets are provided in the input.
No entry-risk mapping to a market or product roadmap can be produced.


Key Takeaways

  • The case identifier and parties are known from the prompt: Regents of the University of Minnesota v. LSI Corporation, 5:18-cv-00821 (D. Minn.).
  • A substantive litigation summary (asserted patents, claim constructions, validity/infringement positions, and outcome) cannot be generated because the input contains no asserted patent numbers, no docket milestone outcomes, and no final disposition or orders.

FAQs

1) What is the docket caption and court for 5:18-cv-00821?
The caption is Regents of the University of Minnesota v. LSI Corporation, with docket number 5:18-cv-00821.

2) Who sued whom in this case?
Plaintiff: Regents of the University of Minnesota. Defendant: LSI Corporation.

3) What are the asserted patents in the complaint?
Not provided in the input.

4) Did the parties reach a settlement or obtain a final judgment?
Not provided in the input.

5) What is the impact of the decision for products implementing the alleged technology?
Not provided in the input.

References

  1. Regents of the University of Minnesota v. LSI Corporation, 5:18-cv-00821 (D. Minn.). (Docket details only as provided in prompt; no further records cited.)

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.